In the first human study of DSIP, the peptide increased total sleep time by 59% and improved nighttime sleep quality without causing any sedation or side effects.
59%Increase in total sleep time within 130 minutes of DSIP infusion compared to placebo, without any detectable sedation on EEG analysis
What the researchers found
When DSIP (delta sleep-inducing peptide) was given intravenously to healthy volunteers, total sleep time increased by 59% within 130 minutes of the morning infusion compared to placebo. Subjects immediately reported a feeling of 'sleep pressure' after receiving the peptide.
DSIP also produced delayed effects on nighttime sleep: shorter time to fall asleep, reduced stage 1 (lightest) sleep, and better overall sleep efficiency. Critically, detailed behavioral and EEG analysis showed no sedation in the traditional pharmacological sense — DSIP appeared to support natural sleep mechanisms rather than forcing unconsciousness. No psychological, physiological, or biochemical side effects were observed.
Why it matters
This was one of the first human studies of DSIP, a peptide originally discovered in rabbit brain dialysate. The finding that it increased sleep by 59% without causing sedation was remarkable — suggesting a fundamentally different mechanism from sleeping pills like benzodiazepines. It supported the idea that DSIP enhances natural sleep architecture rather than drug-induced unconsciousness, making it a conceptual predecessor to modern sleep research focused on restoring physiological sleep patterns.
The numbers in context
n=6 · 59% increase in total sleep time (median) · 25 nmol/kg IV dose · 130-minute observation window · Reduced sleep onset latency at night · Reduced stage 1 sleep · Improved sleep efficiency · No side effects observed
How the study worked
Six healthy volunteers (4 male, 2 female) received either DSIP (25 nmol/kg) or placebo via slow intravenous infusion in the morning in a double-blind crossover design. Subjects underwent extensive psychophysiological monitoring including sleep staging, EEG analysis, and behavioral assessment during the immediate post-infusion period and the subsequent night's sleep.
Who was studied
6 healthy normal volunteers (4 males, 2 females)
What this study cannot tell us
Extremely small sample of only 6 volunteers limits statistical power and generalizability. The 1981 study predates modern sleep research standards and polysomnographic technology. IV administration is impractical for clinical use. No dose-ranging was performed. The 'median' 59% increase in such a small sample may be heavily influenced by individual variation. Long-term safety and efficacy were not assessed.
How to read the evidence
Preliminary evidence from a well-designed double-blind crossover trial, but with only 6 participants. The crossover design adds rigor, but the tiny sample size and 1981 methodology limit confidence in the specific magnitude of effects. The study is historically important as a proof-of-concept.
When this study was published
Published in 1981, this is a historically significant study — one of the first human trials of DSIP. The findings should be interpreted in the context of 1980s sleep research methodology, though the basic observations remain relevant to understanding sleep-peptide biology.
The bigger picture
This pioneering 1981 study launched decades of DSIP research and introduced the concept that a peptide could promote sleep through natural mechanisms rather than sedation. While DSIP never became an approved drug (partly due to its short half-life and difficulty with non-IV delivery), the principle it demonstrated — enhancing natural sleep architecture rather than forcing unconsciousness — has influenced modern sleep research and the development of newer sleep-promoting therapies like orexin antagonists.
Questions still open
- Why did DSIP never become a commercial sleep medication despite this promising early data?
- Could modern peptide delivery methods (nasal, sublingual) make DSIP practical for clinical use?
- Does DSIP's mechanism of enhancing natural sleep differ fundamentally from how orexin antagonists work?
Common questions
What is DSIP and where does it come from?
If DSIP worked so well, why isn't it available as a sleep medication?
Read the original research
Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior.
International journal of clinical pharmacology, therapy, and toxicology, 19(8), 341-5
Citation
Schneider-Helmert, D; Gnirss, F; Monnier, M; Schenker, J; Schoenenberger, G A. (1981). Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior.. International journal of clinical pharmacology, therapy, and toxicology, 19(8), 341-5.